Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-25 @ 9:27 PM
Study NCT ID:
NCT05959356
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2023-07-16
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
Sponsor:
Sun Yat-sen University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11-09
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-07-16
First Submit QC Date:
None
Study First Post Date:
2023-07-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-09
Last Update Post Date:
2025-12-17
Last Update Post Date Type:
ESTIMATED